Celtic Pharma To Invest In Novacta Biosystems
Celtic Pharma Holdings Advisors (CPHA), the advisor to the second Celtic pharma fund, Celtic Pharma Holdings II LP (CP2), would invest in a majority shareholding in Novacta Biosystems
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).